Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

MIT Enterprise Forum New Years Resolutions Networking Event

Summary

Related Content

Regeneron Files Another Complaint Against Amgen in Aflibercept BPCIA Litigation

Recent PTAB Developments for Regeneron’s Aflibercept Formulation Patent

Delaware Court Awards More Than $180 Million for Breach of Commercially Reasonable Efforts Obligation in Drug Development Milestone Dispute

Biosimilar Manufacturers to Expand Offerings in Europe and Japan

Third Circuit Holds That Granting Discovery Under Section 1782 Is Not a “Final” Judgment

New Dental Industry Compliance Standards Take Shape: Dental Trade Alliance (DTA) Releases Revised Code of Ethics

Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector in Europe

Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva

Women in the Life Sciences & Healthcare Sector – Breakfast Networking Event

Lilly to Acquire Verve Therapeutics for Up To $1.3 Billion to Advance One-Time Treatments for People with High Cardiovascular Risk

Goodwin Guides Deep Apple Therapeutics in Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases for up to $812 Million

Deals Require Lot More Work Pre-Signing, Says Goodwin; EQT’s Offer for Swedish Software Biz Moves Forward (PE HUB)

The Legal 500 US 2025 Recognizes 44 Goodwin Practices and 172 Lawyers

Goodwin Advises GRIN Therapeutics in $50 Million Exclusive Collaboration with Angelini Pharma to Develop and Commercialize Radiprodil Outside North America

Goodwin Guides Septerna in Collaboration with Novo Nordisk on Oral Small Molecule Medicines for Obesity and Other Cardiometabolic Diseases for up to $2.2 Billion

American Conference Institute Inaugural Summit on Life Sciences Cyber, Biosecurity and Data Privacy

Life Sciences

Technology